CONCLUSIONS: Patients with FH and ACS have a >2-fold adjusted risk of coronary event recurrence within the first year after discharge than patients without FH despite the widespread use of high-intensity statins. # Clinical Perspective {#article-title-36}
ACS
Watch, Listen, and Learn – Antiplatelet Therapy
Clinical Review: Antiplatelet Therapy Post ACS and Stenting
The clinical review videos from the ACC website are quite good. Make these mandatory for your underwriting staff. They are short and very informative.
